从实验室到临床:AMH和抑制素B在女性生殖健康的变革力量  

From bench to bedside:the transformative power of AMH and inhibin B in reproductive health of women

作　　者：徐慧玉 李蓉[1] Xu Huiyu;Li Rong(State Key Laboratory of Female Fertility Promotion,Center for Reproductive Medicine,Department of Obstetrics and Gynecology,Peking University Third Hospital,Beijing100191,China)

机构地区：[1]女性生育力促进全国重点实验室、北京大学第三医院妇产科生殖医学中心,北京100191

出　　处：《中华生殖与避孕杂志》2025年第1期5-13,共9页Chinese Journal of Reproduction and Contraception

基　　金：国家重点研发计划(2023YFC2705500,2023YFC2705501,2023YFC2705504);北京大学第三医院创新与转化基金(BYSYZHKC2023102,BYSYZHZB2020102)。

摘　　要：抗苗勒管激素(anti-Müllerian hormone,AMH)因其稳定的分泌模式,已成为评估卵巢储备的可靠指标。与此同时,抑制素B在卵泡中期(月经第7天左右)达到高峰,并通过与卵泡刺激素的相互调节,为实时监控卵巢功能提供了独特的洞察。本文深入探讨了AMH和抑制素B在评估卵巢储备及整体生殖健康中的关键作用,还讨论了将AMH和抑制素B与其他临床指标结合,并整合到人工智能工具中的重要性。这种集成技术不仅显著提高了诊断精度,还优化了个性化治疗策略,并推动了卵巢功能评估的准确性和便捷性。此外,本文还展望了这些生物标志物在未来临床实践中的应用前景,强调了其在推动生殖健康管理领域创新和数据驱动应用中的核心作用。Anti-Müllerian hormone(AMH),known for its stable secretion patterns,has become a reliable indicator for evaluating ovarian reserve.Concurrently,inhibin B peaks around the seventh day of the menstrual cycle during the mid-follicular phase and provides unique insights into real-time ovarian function through its regulatory interactions with follicle-stimulating hormone.This article delves deeply into the crucial roles of AMH and inhibin B in assessing ovarian reserve and overall reproductive health.The article also discusses the importance of integrating AMH and inhibin B with other clinical indicators into artificial intelligence tools.This integration significantly enhances diagnostic precision,optimizes personalized treatment strategies,and advances the accuracy and convenience of ovarian function assessments.Furthermore,the article forecasts the future clinical applications of these biomarkers,emphasizing their central role in driving innovation and data-driven applications in reproductive health management.

关 键 词：抗苗勒管激素 抑制素B 卵巢储备 生殖健康 生物标志物 人工智能驱动诊断工具 个性化医疗 

分 类 号：R714[医药卫生—妇产科学]